NetworkNewsBreaks

TuesdayAug 30, 2022 11:39 am

NetworkNewsBreaks – Advisors Mortgage Group Recognized Among New Jersey’s Top 250 Privately Owned Companies for 2022

Advisors Mortgage Group, based in Ocean Township, New Jersey, today announced that it has been recognized by NJBIZ as one of the top 250 privately owned companies in New Jersey in 2022. According to the announcement, Advisors ranked at number 51 on the list, which took into account the number of employees, growth and revenue. “Our growth over the last few years has been due to the dedication of our employees, who triumphed under the uncertainty of the recent pandemic,” said Sean Clark, vice president of Advisors Mortgage Group. “The unexpected housing boom and low interest rates that developed in…

Continue Reading

TuesdayAug 30, 2022 11:32 am

NetworkNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Partners with IBN for Corporate Communications

Cerberus Cyber Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, as its communications partner. Cerberus Sentinel has developed an integrated approach to help clients enjoy a simpler and more successful journey to cyber resilience. The company is rapidly expanding by acquiring world-class cybersecurity and compliance businesses with top-tier talent that offer the latest technology to create innovative protection solutions. IBN offers an investor-based distribution network of more than 5,000 syndication outlets along with newsletters, social media channels, wire services,…

Continue Reading

TuesdayAug 30, 2022 10:49 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

Continue Reading

MondayAug 29, 2022 1:44 pm

NetworkNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Taking MMT(R) Mainstream, Focusing Efforts on ‘Biggest Market for Lidar’

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is taking Micro Motion Technology (“MMT(R)”) mainstream under the guidance of CEO and lidar pioneer Dr. Jun Pei. “Lidar uses lasers to generate 3D images and provides vital information including distance, speed and dimensions. This enables accurate detection tracking of objects based on real-time data. Emerging lidar applications include autonomous vehicles (‘AVs’), advanced driver assistance systems (‘ADAS’), traffic and pedestrian monitoring in smart cities, security and facility management, crowd analytics, and various industrial applications,” a recent article reads. “Cepton offers near-range to ultra-long-range lidar sensors, automotive software…

Continue Reading

MondayAug 29, 2022 1:34 pm

NetworkNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Streamlining NAFTA Region’s Cross-Border Shipping Process

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), through its Fr8App platform, offers a cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. Innovative solutions offer quick and safe cross-border shipments while streamlining daily carrier operations. “The platform functions just as well for domestic, intra-country operations in each of the countries of the United States of America, Mexico or Canada. Because of this and other offerings in the Fr8Tech solutions suite, including but not limited to Fr8Radar, Fr8TMS and Fr8FMS, the company has come to be known for developing solutions to optimize and automate the supply chain process, offering…

Continue Reading

MondayAug 29, 2022 12:20 pm

NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram…

Continue Reading

MondayAug 29, 2022 11:42 am

NetworkNewsBreaks – HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) Announces Option and RSU Grants

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) recently announced that its board of directors has approved the grant of 415,200 incentive stock options, exercisable into the equivalent amount of common shares of the company at a price of C$5.66 per share for a period of five years. According to the update, the grants were made to employees, officers and consultants of the company and are subject certain vesting requirements. HIVE’s board of directors also approved the grant of an aggregate of 1,425,280 restricted share units (“RSUs”), which vest over 24 months, to employees, officers and consultants of the…

Continue Reading

MondayAug 29, 2022 11:04 am

NetworkNewsBreaks – Cerberus Cyber Sentinel Corporation (NASDAQ: CISO) Acquires Santiago, Chile-Based CUATROi

Cerberus Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider based in Scottsdale, Arizona, today announced its completion of the acquisition of CUATROi. Under the terms of the agreement, CUATROi, a cloud, managed services provider and cybersecurity company with headquarters in Santiago, Chile, and offices in Bogotá, Colombia and Lima, Peru, became a wholly owned subsidiary of Cerberus Sentinel. “CUATROi is an excellent cultural fit with the Cerberus Sentinel family of companies,” said David Jemmett, CEO and founder of Cerberus Sentinel. “Cybersecurity is a worldwide problem that requires global capabilities to address the security demands of…

Continue Reading

FridayAug 26, 2022 2:02 pm

NetworkNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) on Target to Own, Control ‘the Elements’ to Supply EV, Renewable Energy, Other Technology Manufacturers

Energy Fuels (NYSE American: UUUU) (TSX: EFR) recently entered into binding agreements to acquire 17 mineral concessions in Brazil. A recent article reads: “The acquisitions, located in the state of Bahia and total approximately 58 square miles, have the potential to provide UUUU’s White Mesa Mill with large quantities of rare-earth-element and uranium-bearing natural monazite sand for decades. “This is another very significant step in Energy Fuels’ development as a major global rare earth element producer based in the United States,” said Energy Fuels CEO and President Mark Chalmers. “We are aggressively seeking to expand our monazite sand feeds. With…

Continue Reading

FridayAug 26, 2022 1:10 pm

NetworkNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion

Odyssey Health (OTC: ODYY), a medical device innovator and biopharmaceutical product developer, has been advancing a proposed solution for brain injury from concussive forces. “Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in. No U.S. Food and Drug Administration (‘FDA’)-approved drug treatment exists for concussion, and medical providers are generally left to rely on prescribed rest to help patients recover. But if Odyssey’s product can be established as safe and effective, it will open doors…

Continue Reading